Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any congenital stationary night blindness in which the cause of the disease is a mutation in the GRM6 gene.
Features include always present findings: Nyctalopia and Congenital stationary night blindness; and common findings: Bone spicule pigmentation of the retina, Myopia, and Horizontal nystagmus. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Congenital stationary night blindness, Horizontal nystagmus |
Bones and joints | 1 | Bone spicule pigmentation of the retina |
Pregnancy and birth | 1 | Congenital stationary night blindness |
Age of onset: adulthood.
GRM6 encodes glutamate metabotropic receptor 6 (877 aa). G-protein coupled receptor for glutamate. Highest expression in Testis (1.9 TPM) and Pituitary (1.5 TPM).
Congenital stationary night blindness 1B is associated with mutations in the GRM6 gene on chromosome 5.
GRM6 is classified as a druggable target (Druggable Genome and G Protein Coupled Receptor categories) with score 3.5.
Genetic testing for GRM6 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features, 3 common features.
No clinical trials have been registered for congenital stationary night blindness 1B.
12 publications have been identified in PubMed for congenital stationary night blindness 1B. Research spans Case Report / Case Series (25%), Basic Science / Preclinical (25%), and Epidemiology / Natural History (25%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 3 | 25% |
Laboratory research | 3 | 25% |
Disease patterns and progression | 3 | 25% |
Research summaries | 2 | 17% |
New treatment approaches | 1 | 8% |
Boranijasevic S (2026). [PMID: 41343198](https://pubmed.ncbi.nlm.nih.gov/41343198/). *JAMA Ophthalmol*. [Case Report / Case Series]
Spanic F (2026). [PMID: 41729106](https://pubmed.ncbi.nlm.nih.gov/41729106/). *Acta Ophthalmol*. [Basic Science / Preclinical]
Taha I (2026). [PMID: 42106701](https://pubmed.ncbi.nlm.nih.gov/42106701/). *BMC Ophthalmol*. [Review / Meta-Analysis]
Kuszel L (2026). [PMID: 42278384](https://pubmed.ncbi.nlm.nih.gov/42278384/). *Int J Mol Sci*. [Epidemiology / Natural History]
Wen L (2025). [PMID: 39652271](https://pubmed.ncbi.nlm.nih.gov/39652271/). *Doc Ophthalmol*. [Case Report / Case Series]
Zhang Y (2025). [PMID: 40181393](https://pubmed.ncbi.nlm.nih.gov/40181393/). *J Transl Med*. [Review / Meta-Analysis]
Sundaramurthy S (2025). [PMID: 40551348](https://pubmed.ncbi.nlm.nih.gov/40551348/). *Acta Ophthalmol*. [Epidemiology / Natural History]
Lin PH (2025). [PMID: 40923695](https://pubmed.ncbi.nlm.nih.gov/40923695/). *Invest Ophthalmol Vis Sci*. [Gene Therapy / Novel Therapeutics]
Hasan N (2025). [PMID: 40766553](https://pubmed.ncbi.nlm.nih.gov/40766553/). *bioRxiv*. [Basic Science / Preclinical]
Pindwarawala M (2025). [PMID: 39681475](https://pubmed.ncbi.nlm.nih.gov/39681475/). *Life Sci Alliance*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center